There is sufficient clinical evidence that the key to decreasing colorectal cancer (CRC) related mortality is early diagnosis through effective screening. A primary focus of the CSM is the development of a CRC specific diagnostic test which will increase early detection which is necessary to prioritise those patients in need for colonoscopy, and to decrease the morbidity and mortality from this disease. The centre aims to clinically validate a minimally invasive, inexpensive, CRC specific serum diagnostic test based on the presence of specific tumour-associated antigens that we have identified in previous work. Our aim is to deliver a serum-based, non-invasive test that can be performed in routine clinical laboratories and will aid in the stratification of patients for colonoscopy. We believe that the development of such a test has the potential to greatly impact on the delivery and quality of clinical services in Ireland and elsewhere. Furthermore, through appropriate future commercialisation, the current clinical project has the potential to increase the capacity of Ireland as a knowledge-based economy.
- CSM Researchers and collaborators discover predictive biomarker for key colorectal cancer drug
- MSc students from the Netherlands visit the CSM
- Our miRNAmeConverter package (https://bit.ly/2fFe5BA) now supports miRBase 22!
- PurinesDX conference April 24th RCSI
- ‘Breast-Predict’ have developed a tool that may predict how effective chemotherapy is likely to be in treating triple-negative breast cancer patients.
- GLIOTRAIN : European Training Network PhD Student Position available
- CoEN Award to CSM-Network of Centres of Excellence in Neurodegeneration
- GLIOTRAIN, Brain Tumor Ireland and RCSI Presents Two Public Lectures- Friday March 9th
- Physiology News Letter 2nd Edition January 2018
- JPND fund the CSM and its partners 1.5M